New Drug Reducing Progression of Primary Progressive MS

Wendy Henderson avatar

by Wendy Henderson |

Share this article:

Share article via email

In this video from the Vall d’Hebron Barcelona Hospital Campus, Dr. Xavier Montalbán talks about the Phase 3 international study of a new drug developed by Roche called ocrelizumab.  The clinical trials have shown that patients with primary progressive multiple sclerosis (PPMS) see a reduction of clinical progression in at least 12 weeks.

The U.S. Food and Drug Administration is giving priority review to a request to approve ocrelizumab as a treatment for PPMS. Read more here.

The new drug gives much hope for those who live with this relatively rare form of multiple sclerosis.

Ocrelizumab is a humanized monoclonal antibody under clinical investigation and development by the Swiss pharmaceutical company Roche. Read more here.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Video